MIR503HG and prostate adenocarcinoma: The data revealed that both, the overall and disease-free survival of patients with PRAD were significantly decreased in patients with high MIR503HG expression (Fig. 1H) indicating that lower MIR503HG expression is beneficial for survival and further supports the notion of an oncogenic role of MIR503HG in PCa.